Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Project Grant - Priority Announcement: Aging

Université Laval

$100,000.00

Preclinical safety, pharmacokinetics, pharmacodynamics, and efficiency of microRNA oligonucleotides for Alzheimer's disease

FY 2019-20

Summary
Alzheimer's disease (AD) is a severe, progressive neurodegenerative disorder causing dementia and ultimately death. Unfortunately, there is no cure for AD and current medications only provide limited and temporary relief. In recent years, much attention has been focused on micro-RNAs as novel therapeutic agents for complex diseases such as cancer and diabetes. This type of small RNA (like DNA) has a strong impact on protein networks important for brain health. As of yet, however, it remains uncertain if and how micro-RNAs can be used to treat neurodegenerative disorders such as AD. For more than a decade, my research team and others have gathered substantial evidence pointing to one particular micro-RNA, namely miR-132, as a prime candidate to treat, delay, or prevent AD. This is based on multiple studies in cells and mice where the delivery of miR-132 can, for instance, restore disease symptoms, including memory. Our goal now is to perform the necessary pre-clinical tests to advance miR-132 to clinical trials in humans. For this, we have already developed specialized tools and methods to deliver miR-132 molecules directly into the brain of mice and non-human primates (monkeys). The next steps involve the biological characterization of these molecules following treatment (e.g., bioavailability, degradation, target engagement). Of course, we will also perform extensive biosafety (toxicology) tests in both animal models. Overall, these cutting-edge studies will provide an essential basis for the development of micro-RNA therapies for AD and related neurodegenerative disorders.
Program
Project Grant - Priority Announcement: Aging
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
414963
Name
Hébert Sébastien
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Neurosciences, Mental Health and Addiction
Theme2
Biomedical
Prcname2
Pharmaceutical Sciences
Projecttitle
Preclinical safety, pharmacokinetics, pharmacodynamics, and efficiency of microRNA oligonucleotides for Alzheimer's disease
Programtype2
Operating Grants
Orgnameinp2
Université Laval
Cihramount2
$100,000
Cihrequipment2
$0
Programname2
Project Grant - Priority Announcement: Aging
Keyworddelim
Gene Silencing; Gene Therapy; Intrathecal; Microrna; Mouse; Non-Human Primate; Oligonucleotide; Pharmacodynamics; Pharmacokinetics; Toxicology
Abstract
Alzheimer's disease (AD) is a severe, progressive neurodegenerative disorder causing dementia and ultimately death. Unfortunately, there is no cure for AD and current medications only provide limited and temporary relief. In recent years, much attention has been focused on micro-RNAs as novel therapeutic agents for complex diseases such as cancer and diabetes. This type of small RNA (like DNA) has a strong impact on protein networks important for brain health. As of yet, however, it remains uncertain if and how micro-RNAs can be used to treat neurodegenerative disorders such as AD. For more than a decade, my research team and others have gathered substantial evidence pointing to one particular micro-RNA, namely miR-132, as a prime candidate to treat, delay, or prevent AD. This is based on multiple studies in cells and mice where the delivery of miR-132 can, for instance, restore disease symptoms, including memory. Our goal now is to perform the necessary pre-clinical tests to advance miR-132 to clinical trials in humans. For this, we have already developed specialized tools and methods to deliver miR-132 molecules directly into the brain of mice and non-human primates (monkeys). The next steps involve the biological characterization of these molecules following treatment (e.g., bioavailability, degradation, target engagement). Of course, we will also perform extensive biosafety (toxicology) tests in both animal models. Overall, these cutting-edge studies will provide an essential basis for the development of micro-RNA therapies for AD and related neurodegenerative disorders.
Competitiondate
201909
Approvedterm2
1 yr 0 mth
Pinamesdelim
Hébert, Sébastien
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $100,000~ $0~
Université Laval - $100,000 Grant (2019-20) | Canada Spends